https://biotechmorning.com/news/merck-winrevair-hyperion-pah-label-update Biotech Morning en 2026-09-23T14:17:08.169Z Merck's PAH Drug Just Put Up a Number That's Hard to Ignore https://biotechmorning.com/news/sjogrens-disease-amgen-dazodalibep-phase-3-win Biotech Morning en 2026-09-23T14:16:21.741Z The Disease Nobody Could Treat Just Met Its Match https://biotechmorning.com/news/celldex-barzolvolimab-phase-3-chronic-hives-safety-concerns Biotech Morning en 2026-09-23T14:15:35.770Z Celldex Aced Its Biggest Exam. Wall Street Still Gave It a Failing Grade. https://biotechmorning.com/news/ulefnersen-fus-als-phase-3-survival-results Biotech Morning en 2026-09-23T14:14:49.656Z The Drug That's Beating One of Medicine's Cruelest Diseases https://biotechmorning.com/news/immunovant-lupus-bet-goes-bust Biotech Morning en 2026-09-23T14:14:06.689Z Immunovant's Lupus Bet Just Went Bust. Now What? https://biotechmorning.com/news/hhs-reduce-animal-testing-drug-development Biotech Morning en 2026-09-23T14:13:22.622Z The U.S. Government Just Told Lab Mice to Start Updating Their Résumés https://biotechmorning.com/news/novartis-boomray-900m-preclinical-radioligand-deal Biotech Morning en 2026-09-23T14:12:38.338Z Novartis Just Paid Up to $900M for a Drug That Doesn't Exist Yet https://biotechmorning.com/news/sarepta-black-box-warning-layoffs-duchenne-3 Biotech Morning en 2026-09-23T14:11:52.901Z Sarepta's Worst Week: A Black Box, 500 Pink Slips, and a $20 Stock https://biotechmorning.com/news/novartis-avidity-second-trial-failure Biotech Morning en 2026-09-23T14:11:05.916Z Novartis Paid $12 Billion for a Platform. Now It's 0-for-2. https://biotechmorning.com/news/white-house-veto-power-nih-grants Biotech Morning en 2026-09-22T14:18:18.490Z The White House Wants Veto Power Over Science Funding https://biotechmorning.com/news/alteogen-novartis-3-billion-subcutaneous-delivery-deal Biotech Morning en 2026-09-22T14:17:37.730Z The $3.2 Billion Bet That You'll Never Sit for an IV Again https://biotechmorning.com/news/novo-nordisk-cagrisema-beats-tirzepatide-weight-loss Biotech Morning en 2026-09-22T14:16:49.520Z Novo Nordisk Just Beat the Best Weight-Loss Drug on the Market https://biotechmorning.com/news/roche-obesity-drug-data-lilly-novo-competition Biotech Morning en 2026-09-22T14:16:05.616Z Roche Just Crashed the Obesity Party. Lilly and Novo Should Be Nervous. https://biotechmorning.com/news/grail-galleri-fda-staff-review-no-major-concerns Biotech Morning en 2026-09-22T14:15:22.411Z A Blood Test That Spots 12 Deadly Cancers Just Cleared Its Biggest Hurdle Yet https://biotechmorning.com/news/nvidia-backed-iambic-therapeutics-ipo-filing Biotech Morning en 2026-09-22T14:14:39.480Z Nvidia's Favorite Drug Company Wants to Go Public https://biotechmorning.com/news/china-25-percent-first-in-class-drug-target-2030 Biotech Morning en 2026-09-22T14:13:56.382Z China Wants to Invent 1 in 4 of the World's New Drugs. By 2030. https://biotechmorning.com/news/adhd-drug-nothing-to-do-with-stimulants Biotech Morning en 2026-09-22T14:13:08.202Z The ADHD Drug That Has Nothing to Do With Stimulants https://biotechmorning.com/news/sarepta-worst-week-gene-therapy-playbook Biotech Morning en 2026-09-22T14:12:21.397Z Sarepta's Worst Week Just Rewrote the Gene Therapy Playbook https://biotechmorning.com/news/viking-therapeutics-obesity-data-spooks-lilly-novo Biotech Morning en 2026-09-22T14:11:38.243Z The $4 Billion Biotech That Just Spooked Obesity's Two Kings https://biotechmorning.com/news/novo-nordisk-strategy-reset-job-cuts Biotech Morning en 2026-09-22T14:10:45.746Z Novo Nordisk Just Torched 4,000 Jobs. Wall Street Still Wasn't Impressed.